UNIGE document Scientific Article
previous document  unige:29633  next document
add to browser collection

Gestion péri-interventionnelle des nouveaux agents antiplaquettaires

Schnyder-Joris, Coralie
Published in Revue médicale suisse. 2013, vol. 9, no. 372, p. 326-30
Abstract The management of antiplatelet drugs in the perioperative setting is based on an individual evaluation of the thrombotic and bleeding risks. When the bleeding risk is deemed low, continuation of the dual antiplatelet therapy is usually recommended, especially in high thrombotic risk settings. When the bleeding risk is deemed moderate, at least one antiplatelet agent should be continued, usually aspirin, and clopidogrel and ticagrelor should be discontinued 5 days and prasugrel 7 days before surgery. In some rare instances of high bleeding risk, discontinuation of aspirin 3 days before surgery is usually acceptable. In high thrombotic settings, bridging with an intravenous antiplatelet drug with a short half-life may be considered.
Keywords Hemorrhage/prevention & controlHumansPerioperative CarePlatelet Aggregation Inhibitors/therapeutic useRisk AssessmentThrombosis/prevention & control
PMID: 23469401
Full text
Research group Geneva Platelet Group (13)
(ISO format)
SCHNYDER-JORIS, Coralie et al. Gestion péri-interventionnelle des nouveaux agents antiplaquettaires. In: Revue médicale suisse, 2013, vol. 9, n° 372, p. 326-30. https://archive-ouverte.unige.ch/unige:29633

256 hits



Deposited on : 2013-09-18

Export document
Format :
Citation style :